Ballentine Partners, LLC Neurocrine Biosciences Inc Transaction History
Ballentine Partners, LLC
- $5.81 Billion
- Q4 2024
A detailed history of Ballentine Partners, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ballentine Partners, LLC holds 1,675 shares of NBIX stock, worth $239,960. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,675Holding current value
$239,960% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
632Shares Held
93.9MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$2.03 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.43 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$738 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$369 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$267 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...